Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Gunale B, Kapse D, Kar S, Bavdekar A, Kohli S, Lalwani S, Meshram S, Raut A, Kulkarni P, Samuel C, Munshi R, Gupta M, Plested JS, Cloney-Clark S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Dharmadhikari A, Bhamare C, Shaligram U, Poonawalla CS, Mallory RM, Glenn GM, Kulkarni PS; COVOVAX-Ped study group. Gunale B, et al. Among authors: lalwani s. JAMA Pediatr. 2023 Jul 31;177(9):911-20. doi: 10.1001/jamapediatrics.2023.2552. Online ahead of print. JAMA Pediatr. 2023. PMID: 37523166 Free PMC article.
Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, Verma V. Sharma HJ, et al. Among authors: lalwani sk. Hum Vaccin. 2011 Apr;7(4):451-7. doi: 10.4161/hv.7.4.14208. Epub 2011 Apr 1. Hum Vaccin. 2011. PMID: 21403463 Clinical Trial.
Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process.
Sharma HJ, Patil VD, Lalwani SK, Manglani MV, Ravichandran L, Kapre SV, Jadhav SS, Parekh SS, Ashtagi G, Malshe N, Palkar S, Wade M, Arunprasath TK, Kumar D, Shewale SD. Sharma HJ, et al. Among authors: lalwani sk. Vaccine. 2012 Jan 11;30(3):510-6. doi: 10.1016/j.vaccine.2011.11.067. Epub 2011 Nov 26. Vaccine. 2012. PMID: 22119927 Clinical Trial.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.
Amdekar YK, Lalwani SK, Bavdekar A, Balasubramanian S, Chhatwal J, Bhat SR, Verghese VP, Tansey SP, Gadgil D, Jiang Q, Pride M, Emini EA, Gruber WC, Scott DA. Amdekar YK, et al. Among authors: lalwani sk. Pediatr Infect Dis J. 2013 May;32(5):509-16. doi: 10.1097/INF.0b013e31827b478d. Pediatr Infect Dis J. 2013. PMID: 23190777 Clinical Trial.
A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.
Dalvi S, Kulkarni PS, Phadke MA, More SS, Lalwani SK, Jain D, Manglani M, Garg BS, Doibale MK, Deshmukh CT; SIIL DTwP + HepB Hib Author Group. Dalvi S, et al. Among authors: lalwani sk. Hum Vaccin Immunother. 2015;11(4):901-7. doi: 10.1080/21645515.2015.1010953. Hum Vaccin Immunother. 2015. PMID: 25933183 Free PMC article. Clinical Trial.
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O. Lalwani S, et al. BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202. BMJ Open. 2015. PMID: 26362659 Free PMC article. Clinical Trial.
251 results